Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Good data is essential for a successful study. Whilst analysis is important, standardisation in the clinic is imperative.

30
August 2011

View Articles

Join Richmond Pharamcology at the 2nd DIA Cardiac Safety Workshop in Japan for our latest TQT Analysis in Japanese and Caucasian Volunteers

16
August 2011

View Articles

Richmond Pharmacology Celebrates 10 Years at the Henley Royal Regatta

4
August 2011

View Articles

Join Richmond Pharmacology at this year's 10th Annual Congress of the European Association for Clinical Pharmacology

16
May 2011

View Articles

Cardiovascular Safety in Drug Development: State-of-the-Art Assessments

25
March 2011

View Articles

TQT Analysis in Japanese and Caucasian Volunteers

15
March 2011

View Articles

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event